CorMedix Inc. — Director's Dealing 2013

Sep 23, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2013-09-20

Reporting Person: MILBY RANDY (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-09-20	Common Stock, $0.001 par value per share	C	142857	$0.35	Acquired	142857	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-03-20	Stock Option (right to buy)	$0.9	A	500000	Acquired	2023-03-20	Common Stock, $0.001 par value per share (500000)	Direct
2013-09-20	Senior Convertible Note (convertible into Common Stock)	$0.35	C	142857	Disposed	2013-09-20	Common Stock, $0.001 par value per share (142857)	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.68	2022-12-05	Common Stock, $0.001 par value per share (100000)	100000	Indirect
Warrant (right to purchase Common Stock)	$0.4	2017-09-20	Common Stock, $0.001 par value per share (125000)	125000	Indirect
Stock Option (right to buy)	$0.29	2022-05-14	Common Stock, $0.001 par value per share (50000)	50000	Indirect

Footnotes

F1: The reporting person beneficially owns these securities through his ownership interest in MW Bridges LLC (an entity through which he has voting and investment control).

F2: These options vest based on performance milestones running through December 31, 2014.

F3: These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.

F4: On September 20, 2012, the reporting person, through his ownership in MW Bridges LLC (an entity through which he has voting and investment control), acquired in a private placement $50,000 of (i) 9% Senior Convertible Notes, convertible into shaers of the Company's Common Stock, $0.001 par value per share, at a conversion price of $0.35 per share, which were converted on September 20, 2013; and (ii) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.

F5: These options vested 100% upon receipt of CE Mark approval for the Company's Neutrolin product candidate on July 5, 2013.